Background. Primary focal segmental glomerulosclerosis (FSGS) frequently recurs after kidney transplantation (KTx) in children. This can lead to delayed graft loss. As the management of children with recurrent FSGS is not well established, apheresis strategies could be a cornerstone to control the disease. Immunoadsorption (IA) is a recent apheresis therapy. There have been few studies examining IA in this setting. We report the results of IA for management of recurrent FSGS after KTx in children in France. Methods. We included all children treated with IA for early FSGS recurrence after KTx between January 2011 and June 2014 in France. We excluded genetic forms of FSGS. Patients' characteristics and technical data on IA were retrospectively collected. Recurrence was defined as nephrotic proteinuria during the post-transplantation period. Partial and complete remissions were defined when urine protein:creatinine ratios were less than 0.2 and 0.05 g/mmol, respectively. Results. Twelve patients, from six paediatric KTx units, presenting with FSGS recurrence between 0 and 21 days after KTx were treated with IA. Ten of 12 children were responders: 2 achieved partial remission and 8 complete remission. The decrease of proteinuria rapidly occurred within the first 10 sessions after initiating IA. After 3 months of IA, two patients maintained remission without IA and eight became IA dependent. No severe side effects were reported. Conclusions. Our study reports on the efficacy of IA in the recurrence of FSGS after KTx in children. Further prospective controlled studies are required to confirm these results and to optimize the management of FSGS recurrence after paediatric KTx.
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I N T R O D U C T I O N
Primary focal segmental glomerulosclerosis (FSGS) is the most common primary glomerular disorder in children, revealed by oedema and nephrotic proteinuria. Some children, despite steroids and immunosuppressive therapies, continue to have nephrotic proteinuria and progress to end-stage renal failure (ESRF). Approximately 30% of these patients experience a recurrence of FSGS within the first few days after kidney transplantation (KTx), leading to graft loss in half of these cases [1, 2] . The highest risk of disease recurrence is observed in patients who rapidly progressed to ESRF and in patients who lost their first graft due to FSGS recurrence [3, 4] . The management of patients with FSGS recurrence after KTx is challenging and is not well defined due to a lack of controlled studies. Most paediatric centres treat recurrent FSGS with intensification of immunosuppression such as pulse steroids, high-dose cyclosporine A (CsA), cyclophosphamide in combination with apheresis therapy and, more recently, rituximab [5] [6] [7] [8] . Two reviews summarize these therapeutic options based on results from small series [4, 9, 10] . Both therapeutic plasma exchange (TPE) and immunoadsorption (IA) have been evaluated with FSGS because a circulating permeability factor has been suggested to play a role in the pathogenesis of this disease [3] . Studies have demonstrated a partial efficacy of TPE in children with FSGS [2, 6, 11] . In 2013, the American Society for Apheresis (ASFA) recommended TPE in combination with increased immunosuppression to treat recurrent FSGS [12] . However, TPE induces a loss of coagulation factors responsible for side effects such as postoperative bleeding. In contrast to TPE, IA is a selective apheretic procedure. Dantal et al. [13] demonstrated a beneficial effect of IA therapy in adults with relapse of FSGS after KTx. Reports on the use of IA in children with recurrent FSGS after KTx are scarce. Paediatric cases published as case reports or in adult series also reported the efficacy of IA in all cases [14] [15] [16] [17] [18] . However, no paediatric cohort has yet been published. IA therapy has been available in French paediatric nephrology units since 2011. This study reports the French experience of IA for the management of paediatric recurrent FSGS after KTx.
M A T E R I A L S A N D M E T H O D S

Patients
We conducted a retrospective review across all French paediatric KTx centres to select patients with recurrent FSGS post-transplantation treated with IA. All children (ages 1-15 years) presented were histologically confirmed with primary FSGS resulting in ESRF. They underwent KTx at a paediatric age, i.e. <18 years of age. They were treated with IA between January 2011 and June 2014 for recurrence in the post-transplantation period. We excluded secondary FSGS, including genetic forms. Data related to patients' characteristics, biological tests and therapeutic strategies were retrospectively reviewed. Data on the technical characteristics of IA sessions were also collected, including dates of sessions, volume of plasma processed and percent reduction of immunoglobulin G (IgG). The ethics committees of all participant institutions approved the collection and publication of the data for all patients presented.
Definitions
Recurrence was defined as the occurrence of nephrotic-range proteinuria after KTx [urine protein:creatinine (UPCR) ratio >0.2 g/mmol]. The primary outcome was UPCR, used to assess IA response. Partial remission was arbitrarily defined as a UPCR between 0.2 and 0.05 g/mmol. Complete remission was defined as a UPCR <0.05 g/mmol. Sustained complete remission was defined as complete remission being maintained without relapse after stopping apheresis at the time of data collection. The delay between the first IA session and remission was expressed in days and in the number of IA sessions. IA was classified as a failure when proteinuria was still nephrotic after 20 sessions of IA. Apheresis dependence was considered when patients required TPE or IA therapy 3 months after post-transplantation relapse to maintain UPCR between 0.2 and 0.05 g/mmol. Graft failure was defined as returning to renal replacement therapy.
Technical characteristics of IA sessions
IA procedures were performed either with a protein A column (Immunosorba, Art/Adasorb, Fresenius Medical Care) or with an IgG column (Therasorb, Ig flex, Life18, Miltenyi Biotec), according to the availability of machines in the different centres. Previous studies showed that both protein A and IgG columns were strongly effective in retaining Ig and in reducing albuminuria in FSGS [13] . IA therapy started intensively and was gradually discontinued, according to medical experiences and the availability of machines. Patients received intravenous Ig supplementation after each IA session to replace depleted antibodies. Depending on the centre, adsorbers were replaced either every 10 sessions as recommended by the manufacturer or if the reduction of IgG was <80% or in case of a technical problem. Data on IgG circulating levels were immediately collected before and after the IA session. Physicians defined the plasma volume processed per each session. Data were presented as mean 6 SD or median (range).
R E S U L T S
Patients' characteristics and pre-transplantation data Twelve patients from six French paediatric KTx units were included in the study. Clinical features at presentation and treatments of the 12 patients are displayed in Table 1 . The median age at diagnosis of nephrotic syndrome was 4.8 years. The sex ratio was 1. All patients received oral steroids except one due to late discovery of the disease at chronic kidney disease stage 4 (Patient 1; Table 1 ). One of the cases was steroidsensitive FSGS at onset and became secondarily resistant to steroids. All other patients were initially steroid resistant. All patients but one were treated with calcineurin inhibitors (CNIs). Two patients were treated with ineffective TPE. None of the cases were treated with IA before KTx. Whatever immunosuppressive treatments were provided, the patients progressed quickly to ESRF [median time to ESRF 2.2 years (range 0.8-7.2 years)]. All of them required dialysis before KTx.
KTx data
KTx occurred at a median age of 10.5 (range 6.1-16.0) years. It was the first renal graft for all cases except one, who received a second renal graft. All patients received a cadaveric renal transplant. The median cold ischaemic time was 16.8 (range 10.0-30.0) h. Five of 10 patients had pre-transplantation antihuman leucocyte antigen (HLA) antibodies. The median HLA mismatch score was 3 (range 0-4). Induction immunosuppressive therapy included basiliximab (n ¼ 9) or antithymocyte globulin (n ¼ 3), intravenous CsA (n ¼ 6) or oral tacrolimus (n ¼ 6), mycophenolate mofetil (MMF) (n ¼ 10) or azathioprin (n ¼ 2; patients 11 and 12) and steroids (n ¼ 12). Because of a significant risk of recurrence, one patient received rituximab before KTx (Patient 1) and two patients had preventive apheresis therapy hours before KTx (IA: Patient 1; PE: Patient 4). All patients received sulfamethoxazole-trimethoprim as prophylaxis against Pneumocystis carinii. For cytomegalovirus or EpsteinBarr virus mismatch risk, the medical attitude was not homogeneous among centres: some patients received valganciclovir during 6 months, while the others had no prophylaxis but an intensive follow-up of viral loads.
Recurrence of FSGS
All patients experienced early FSGS recurrence, with a median time of 4.5 (range 0-21) days after KTx. The median peak UPCR before starting IA therapy was 1.2 (range 0.2-4.2) g/ mmol and the median serum albumin was 28 (range 20-37) g/ L. Renal graft biopsies, performed in four patients the day after the recurrence, were normal in two cases and showed borderline rejection in two cases.
Management of recurrence of FSGS
For all patients, the management of FSGS included increased immunosuppressive therapy, apheresis and the addition of anti-proteinuric drugs such as angiotensin-converting enzyme inhibitors (ACEIs) and/or angiotensin receptor blockers (ARBs). The timing and management of recurrent FSGS are displayed in Table 2 .
Immunosuppressive drugs. All patients had already received steroids as induction immunosuppressive therapy either as a pulse of methylprednisolone or as a high dose of oral prednisone. The scheme of CNI therapy was changed in three cases: from tacrolimus to intravenous CsA (n ¼ 2) and from CsA to tacrolimus (n ¼ 1). For five patients, target levels of CNI were increased immediately after recurrence (T0 tacrolimus $15 ng/mL; T0 CsA 300 ng/mL and T2 CsA 1000 ng/mL) and the dose of CNI was adjusted accordingly. Borderline rejections were also treated with increasing immunosuppression. In summary, eight patients were treated with intravenous CsA prior to apheresis. In addition to Patient 1 treated before KTx with rituximab, 10 patients received rituximab (375 mg/m 2 body surface area, median number of doses 2). Among them, seven received rituximab during the IA period; the other three had received rituximab at the time of TPE (Patients 7, 8 and 11). Other therapies used before IA, during IA and after IA are described in Table 2 .
Apheresis. Data concerning the management of FSGS recurrence are presented in Table 2 ; results of IA are summarized in Tables 3 and 4 .
Six patients initially received TPE before IA. The TPE procedures were started between 1 and 10 days after recurrence. Six patients were treated with IA only; in these cases IAs were begun immediately after FSGS recurrence, namely between 0 and 4 days after recurrence.
In Table 4 we present the two categories of patients: eight with an early initiation of IA (without TPE or in rescue of TPE failure) and four with a long delay between recurrence of the disease and initiation of IA (226-1644 days).
Results of IA
A total of 501 IA sessions were performed. Three patients (Patients 5, 7 and 10) were treated with a protein A column and nine with an IgG column. The median patient age at the first IA session was 11.8 (range 6.1-16.1) years and median body weight was 32.5 (range 21-67) kg. They had a median of 4.2 sessions during the first week after the first IA and 2.5 sessions during the second week. Sessions lasted a median of 129 (range 85-240) min. The median plasma volume processed per session was 128 mL/kg (3.2 plasma volumes processed per session; n ¼ 11). The only reported side effect was an anaphylactoid reaction in Patient 5: in this specific case, the columns had been conserved for a long time at À4 C (1 month) without using them, corresponding to a therapeutic window of IA. During this period, IAs were withdrawn to evaluate a potential response to abatacept. The anaphylactoid reaction occurred when IA sessions were restarted. An exhaustive allergic investigation did not find a real allergic reaction and no other side effects were reported after the replacement of columns.
All children had nephrotic proteinuria before starting IA, except one patient (Patient 7) who was successfully treated with TPE. Eight patients achieved complete remission, two achieved partial remission and two had no remission after IA (Table 3) .
For the group with early initiation of IA, two patients (Patients 10 and 11) received IA in rescue of inefficient TPE, and we noticed that the efficacy of IA was not superior to TPE. Two patients had a complete sustained remission after stopping IV, intravenous; FK, tacrolimus; RTX, rituximab; cycloph, cyclophosphamide.
IA (Patients 1 and 2 ). In patients with IA dependence, the level of UPR was variable (from 0.01 to 0.6 g/mmol). Patient 6 was switched to TPE due to a problem of availability of IA in the medical centre. For the second group (i.e. delayed IA), IA seems to be superior to TPE in Patients 8 and 9, nevertheless IA was also stopped because the treatment was considered too constraining. Patient 4 was initially partially treated with TPE after recurrence, then by other therapies without efficacy. Fifty-four months after KTx he was successfully treated with IA. This therapy was stopped because he had good graft function 5 years after KTx and because of the bad quality of life of the treatment. Physicians considered IA as rescue therapy for him in the event his graft function deteriorated. Finally, Patient 7 received IA with the hope of decreasing in the number of apheresis sessions, but the results were equal with IA and he was switched to TPE because of the cost of the technique. The median follow-up time was 16 months after KTx and 13 months after the first IA session. At the end of the follow-up, IA was continued in three patients and TPE was continued in two patients.
IA removed Igs from plasma, resulting in a mean decrease in their circulating levels of 72 6 8.7% for IgG (n ¼ 10), 51 6 10.6% for IgA (n ¼ 9) and 45 6 11.4% for IgM (n ¼ 9). The mean percent reduction of IgG, IgA and IgM was 70 6 8.8%, 32 6 6.4% and 44 6 4%, respectively, with a protein A column (n ¼ 3) and 72 6 6.7% for IgG (n ¼ 7), 61 6 11% for IgA (n ¼ 7) and 46 6 11.5% for IgM (n ¼ 7) with an IgG column. Figure 1 illustrates the evolution of IgG levels during IA therapy per patient.
Graft outcomes
None of the patients experienced graft rejection during the follow-up, however, two patients had borderline rejection on initial biopsy. Systematic graft biopsies performed 3 months after KTx in 11 patients showed normal renal tissue, no segmental glomerular sclerosis, no signs of rejection, all Banff items equal to zero with negative C4d. Four patients had other biopsies. Two biopsies performed at 6 months showed mesangial hypercellularity (Patients 3 and 4). One patient (Patient 3) experienced concurrently a severe BK virus nephropathy 6 months after KTx, documented by increased viraemia, histologic lesions and elevation of serum creatinine. Immunosuppressive therapies were decreased to control this graft complication (monotherapy with T0 tacrolimus 5 ng/ mL). Two biopsies performed at 1 year after transplantation were normal (Patients 1 and 2) . At the end of the follow-up, all patients had functioning grafts.
D I S C U S S I O N
The management of recurrent FSGS in both adults and children is still a matter of debate. Several therapeutic options have been attempted, including apheresis procedures. Only six paediatric cases of IA have been reported but no paediatric cohort has been published. This study aims at reporting the effects of IA on proteinuria in a cohort of paediatric renal recipients with recurrent FSGS. Despite great heterogeneity in our cohort concerning the delay of initiation of IA, results of our series of 12 children were encouraging and confirmed the safety and benefit of IA. In 1994, Dantal et al. [14] reported the first paediatric case of recurrent FSGS successfully treated with IA. Since this influential publication, five other cases have been published individually [15] [16] [17] [18] , summarized in Table 5 . Our study demonstrated a beneficial effect of IA in 10 of 12 patients (83%). Previously published results reported a higher success rate of IA. However, the initial response as a complete remission defined by a UPCR <0.05 g/mmol was reached in our cohort in 8 of 10 patients (versus 2 of 6 in previously published cases). Two patients in our cohort maintained complete remission after a short series of IA, confirming what had previously been reported in both children and adults [14, 18] . Among responder patients, the response occurred rapidly after initiating IA therapy. The UPCR decreased below the nephrotic range before the 10th session and was <0.05 g/ mmol before the 12th session in patients with complete remission. Dantal et al. [14] reported a similar rapid effect of IA. Unfortunately, for eight children in our series, the effect of IA was limited in time and patients needed chronic IA-between one and three sessions per week-to maintain remission. In our cohort we defined two types of clinical profiles that are differentiated by the level of IA dependence. Some children were slightly dependent and others were highly dependent on IA. In highly dependent patients, the frequency of sessions impacts their quality of life. Although effective, IA could be stopped if their quality of life is unacceptable.
No comparison trial between TPE and IA in recurrent FSGS in children has been conducted. Half of children in our cohort received TPE before IA, with TPE being effective in four cases (67%), similar to previously published results [5, 8] . In patients treated with early IA, we did not notice a clear benefit of IA compared with TPE (Patients 10 and 11). We could only highlight that no side effect, particularly bleeding, was observed in patients undergoing IA in a context of recent surgery. In patients treated with IA with a long delay from recurrence, IA seemed to be better than TPE only in Patients 8 and 9, switched from chronic treatment with TPE to IA; nevertheless, the quality of life with a high dependence on IA was not acceptable and the technique was stopped. In Patient 4, tested 54 months after the recurrence, no conclusion could be drawn, recognizing that the FSGS response to different therapies can evolve over time. Because our patients received several concomitant immunosuppressive therapies, we cannot affirm that the decrease in proteinuria was only due to IA. Combined use of IA and other therapies may increase the efficacy of both treatments.
Because of the limited number of patients and the heterogeneity of the cohort, we failed to show a difference between the responder and the non-responder patients. However, we tried to identify factors influencing IA response.
We initially focused on the two patients who did not respond to IA. Patient 11 received only 10 sessions, which was probably an insufficient number to conclude the failure of IA. Indeed, even though the response occurred rapidly in the main responder patients (median number of sessions to achieve a negative proteinuria was 4), one patient needed 9 and 11 sessions to obtain partial and complete remission, respectively. We therefore suggest that a minimum of 15 or 18 sessions (3 sessions per week for 5-6 weeks) should be performed before concluding the absence of efficacy of the IA technique. Despite some physicians suggesting that high levels of IgG supplementation is beneficial to avoid circulating factor production and to improve the clearance of circulating immune complexes, we note that Patient 12 failed to decrease his proteinuria with IA despite higher doses of IgG supplementation than the other patients. We could also hypothesize that in this technique, high-dose Ig could saturate adsorbers, limiting extraction of the circulating factor responsible for FSGS. However, at this stage a consensual dose of intravenous Ig cannot be established, because of the lack of bibliography and comparative/prospective studies. Moreover, due to the retrospective design of this study, we did not seek to determine the superiority of the protein A or IgG column used for the IA technique.
The efficacy of anti-proteinuric renin-angiotensin-aldosterone system treatment was not studied in this cohort because of the heterogeneity and the dose variations of medication over time, depending on circulating creatinine and electrolytes. However, we cannot rule out that anti-proteinuric therapies could have influenced the evolution of UPCR, especially in patients receiving delayed IA.
The immunosuppressive maintenance therapy could also influence remission. All patients received steroids, anti metabolites and CNI. The two non-responder patients received azathioprine as an antimetabolite. Since MMF had benefits in cortico-dependent nephrotic syndrome, we might wonder if MMF is involved in inducing remission of recurrent FSGS. Almost all patients received rituximab, but we noted that one of the two patients with complete and sustained remission received it before transplantation; nevertheless, because of the data disparities, it was not possible to determine the efficacy of rituximab in post-transplant recurrence of FSGS.
Concerning preventive treatment, some recent reports have suggested that prophylactic TPE before transplantation could have a preventive role against recurrence [19, 20] . However, Gonzalez et al. [21] reported that TPE did not decrease the rate of FSGS recurrence but might be beneficial in treating high-risk patients, e.g. previous graft secondary to recurrence. Similar experiences have been reported with IA in an adult cohort [22] . In our series, two patients had preventive apheresis hours before KTx. Interestingly, the only child who had preventive IA presented complete and sustained remission after IA. Finally, we have to keep in mind that rare spontaneous remissions of FSGS have been described in the literature [23] [24] [25] .
Our study had several limitations, including the retrospective design, the use of several treatment protocols and the absence of a control group, due to the scarcity of pathologic cases. There was no control group because there is no gold standard treatment for recurrent FSGS after KTx. Nevertheless, we reported the results of the first paediatric cohort, well-defined inclusion criteria and long-term and detailed follow-up. To date, there is no guideline on management of IA in recurrent primary FSGS after KTx, and it would be interesting to have a standardized practice. In 2010, Vinai et al. [4] proposed a management algorithm for children with recurrent FSGS after KTx. Today, following recent published results, it appears justified that IA is now proposed alongside TPE as soon as recurrence is diagnosed. Based on the literature review and our experience, we propose the algorithm illustrated in Figure 2 .
In conclusion, we reported the efficacy and safety of IA in 10 of 12 children treated for recurrent FSGS after KTx. IA can be considered as a therapeutic options in the recurrence of FSGS after KTx and is an alternative therapy to TPE due to its more selective performance. Additional follow-up will be required to determine the long-term prognosis for these patients. Suggested algorithm for a method of surveillance and treatment of recurrent FSGS after KTx in children. *Intensive means at least 3 IA sessions per week for 6 weeks (i.e. at least 18 sessions) and at least 5 daily consecutive TPE sessions (repeated once if necessary). **With the limits of our study, we suggest at least a substitution dose of IVIG (0.2-0.4 g/kg) after each IA session; higher doses should be evaluated in further studies. ESRD, end-stage renal disease; IVIG, intravenous immunoglobulin.
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A B S T R A C T
Background. There are limited data on secular trends in the incidence of end-stage renal disease (ESRD) and frequencies of its risk factors or treatment modalities in patients with immunoglobulin A nephropathy (IgAN). Methods. This study divided 1255 patients with IgAN into three groups according to the timing of renal biopsy: 1979-89 (n ¼ 232), 1990-99 (n ¼ 574) and 2000-10 (n ¼ 449). The ageadjusted incidence rates, incidence rate ratios and 95% confidence intervals (CIs) for ESRD were calculated by the person-year method and compared using Poisson regression analysis. Results. A total of 63 patients (5.0%) developed ESRD. The ageadjusted incidence of ESRD decreased significantly over time, i.e. 11.5 per 1000 person-years (95% CI 5.4-24.6) in 1979-89, 6.5 per 1000 person-years (95% CI 1.0-25.2) in 1990-99 and 4.2 per 1000 person-years (95% CI 1.0-17.7) in 2000-10. The proportions of patients with preserved renal function and acute-stage inflammatory histologic changes (i.e. endocapillary hypercellularity and extracapillary proliferation) at the timing of biopsy increased over time, as did the rates of prescriptions of renin-angiotensin system blockers and corticosteroids (all P for trend <0.05). The effect of acute inflammatory histologic lesions on renal prognosis was drastically reduced over time. Conclusions. These findings suggest that early diagnosis in the acute inflammatory phase and subsequent aggressive treatment may have contributed to the significant downward trend in the incidence of ESRD in patients with IgAN over three decades.
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I N T R O D U C T I O N
The number of individuals with chronic kidney disease (CKD) is increasing rapidly, and CKD is emerging as a major worldwide public health concern. Following diabetic nephropathy, glomerulonephritis is the second most frequent cause of endstage renal disease (ESRD) among patients with CKD [1] . Immunoglobulin A nephropathy (IgAN) is the most common type of primary glomerulonephritis occurring worldwide [2, 3] . Renal prognosis in the majority of patients with mild IgAN is generally good, although it is relatively poor in some progressive cases. For example, a study analyzing Japanese patients with IgAN found that the 5-, 10-, 15-and 20-year renal survival rates were 96, 85, 75 and 61%, respectively [4] . Long-term prognosis depends largely on early risk stratification at the time of diagnosis, suggesting the need for strategies that prevent disease progression in patients with IgAN.
The concept of CKD has emphasized the importance of early detection of kidney disease and appropriate referral to nephrologists [5] . Changes in lifestyles and treatment modalities over
